<DOC>
	<DOCNO>NCT02573220</DOCNO>
	<brief_summary>This phase I trial study side effect best dose irinotecan hydrochloride , base genetic test , give combination fluorouracil , leucovorin calcium , cetuximab first-line therapy treat patient abnormal gene call RAS wild-type spread part body ( metastatic ) . Patients may also gene call uridine diphosphate glucuronosyltransferase ( UGT1A1 ) may interfere way irinotecan hydrochloride absorbed body may able tolerate . Determining presence gene may help determine best dose irinotecan hydrochloride give fluorouracil leucovorin calcium ( FOLFIRI ) . Combination chemotherapy , FOLFIRI , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Cetuximab may stop growth tumor cell block enzymes need cell growth . Giving FOLFIRI together cetuximab may better treatment patient colorectal cancer .</brief_summary>
	<brief_title>Irinotecan Hydrochloride With FOLFIRI Cetuximab First-Line Therapy Treating Patients With RAS Wild-Type Colorectal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To define maximum tolerate dose ( MTD ) , dose limit toxicity ( DLT ) phase II recommend dosage irinotecan ( irinotecan hydrochloride ) administer FOLFIRI regimen plus cetuximab metastatic colorectal cancer ( mCRC ) patient *1/*1 *1/*28 uridine diphosphate glucuronosyltransferase ( UGT1A1 ) genotype treat first line chemotherapy . SECONDARY OBJECTIVE : To estimate response rate , progression-free survival ( PFS ) metastasectomy ( curative intent ) rate overall patient population ( genotype cohort ) . OTHER OBJECTIVES : I . To evaluate variability irinotecan pharmacokinetics , combination cetuximab , patient *1/*1 *1/*28 genotype effect pharmacokinetic profile toxicity response rate . II . To evaluate pharmacokinetic profile irinotecan major metabolite absence presence cetuximab administration , order define effect chimeric monoclonal antibody irinotecan pharmacokinetics . OUTLINE : This dose-escalation study irinotecan hydrochloride patient UGT1A1 . Patients receive irinotecan hydrochloride intravenously ( IV ) 1-2 hour , fluorouracil IV continuously 46 hour , leucovorin calcium IV day 1 15 . Patients also receive cetuximab IV 2 hour day 3 15 course 1 day 1 15 subsequent course . Courses repeat every 28 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis mCRC RAS wildtype status ( Clinical Laboratory Improvement Amendments [ CLIA ] certify assay include known mutation Kirsten rat sarcoma viral oncogene homolog [ KRAS ] , Harvey rat sarcoma viral oncogene homolog [ HRAS ] , neuroblastoma RAS viral ( vras ) oncogene homolog [ NRAS ] ) No prior chemotherapy metastatic disease Able understand provide write informed consent Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy &gt; 3 month Measurable evaluable disease define Response Evaluation Criteria Solid Tumors ( RECIST , version 1.1 ) criterion , i.e . lesion accurately measure least one dimension long diameter &gt; = 20 mm use conventional technique &gt; = 10 mm use spiral compute tomography ( CT ) scan Absolute neutrophil count ( ANC ) &gt; l500/ul Hemoglobin &gt; 9g/dL Platelets &gt; 100,000/ul Total bilirubin = &lt; 1.5 time upper limit normal Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 time upper limit normal Alkaline phosphatase &lt; 2.5 time upper limit normal , unless bone metastasis present absence liver metastasis Creatinine &lt; 1.5 mg/dL Patients genotyped UGT1A1*28 polymorphism *1/*1 *1/*28 genotype Men woman childbearing potential must agree use adequate contraception ( double barrier birth control ) duration study therapy Negative serum urine betahuman chorionic gonadotropin ( hCG ) pregnancy test screening patient childbearing potential Patients variant allele ( *28/*28 ) Patients polymorphism UGT1A1 *1 *28 ( e.g , *6 ) Uncontrolled severe cardiovascular disease , include myocardial infarct unstable angina within 6 month prior study treatment , New York Heart Association ( NYHA ) class II great congestive heart failure , serious arrhythmia require medication treatment , clinically significant pericardial disease cardiac amyloidosis Patients specific contraindication use antiEGFR therapy pulmonary fibrosis , interstitial pneumonia history Unresolved diarrhea bowel obstruction Active bleeding Documented cerebral metastasis Serious active infectious disease Pregnancy Radiotherapy major surgery within 4 week Psychiatric illness social situation would limit compliance study requirement Presence previous concomitant neoplasm exclusion situ cervical cancer Patients take substrate , inhibitor inducer CYP3A4 encourage switch alternative drug whenever possible , give potential drugdrug interaction irinotecan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>